SCHEMBL1379980

SCHEMBL1379980

O=C(NCCO)c1ccc2c(c1)ncn2-c1ccc(OCCCOc2ccc(F)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.61
MEN1 O00255 5/20 0.61
HPGD P15428 3/20 0.60
MAPK1 P28482 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
NPC1 O15118 1/20 0.57
MAPT P10636 4/20 0.52
TP53 P04637 4/20 0.52
ALDH1A1 P00352 1/20 0.50
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
FGFR1 P11362 1/20 0.48
SRC P12931 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1378843 0.91 HPGD (0.72) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL4505163 0.90 KMT2A (0.67) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1378082 0.89 KMT2A (0.60) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1377140 0.89 KMT2A (0.67) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1380975 0.88 HPGD (0.74) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1381505 0.88 KMT2A (0.61) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1377927 0.86 MEN1 (0.55) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1381949 0.86 KMT2A (0.61) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1381992 0.86 HPGD (0.59) KMT2AMEN1HPGDMAPK1CYP1A2
SCHEMBL1378868 0.85 MEN1 (0.59) KMT2AMEN1HPGDMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4769720-B2 2011-09-07 JP claimed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US claimed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP claimed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K KMT2A 518/4885MEN1 979/4885HPGD 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.